Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial.
Lancet Haematol
; 5(3): e117-e126, 2018 Mar.
Article
in En
| MEDLINE
| ID: mdl-29396092
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Thrombocytopenia
/
Thrombopoietin
/
Myelodysplastic Syndromes
/
Recombinant Fusion Proteins
/
Receptors, Fc
/
Leukemia, Myeloid, Acute
Type of study:
Clinical_trials
/
Diagnostic_studies
/
Etiology_studies
/
Guideline
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Female
/
Humans
/
Male
Language:
En
Journal:
Lancet Haematol
Year:
2018
Document type:
Article
Country of publication:
Reino Unido